Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs.

Martinello M, Dore GJ, Matthews GV, Grebely J.

Infect Dis Clin North Am. 2018 Jun;32(2):371-393. doi: 10.1016/j.idc.2018.02.003. Review.

PMID:
29778261
2.

Management of acute HCV infection in the era of direct-acting antiviral therapy.

Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV.

Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):412-424. doi: 10.1038/s41575-018-0026-5. Review.

PMID:
29773899
3.

Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.

Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL, Tu E, Marks P, Pagani N, Grebely J, Nelson M, Matthews GV.

J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12917. [Epub ahead of print]

PMID:
29660224
4.

Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.

Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME.

J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25051. doi: 10.1002/jia2.25051.

5.

Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014).

Waziry R, Grebely J, Amin J, Alavi M, Hajarizadeh B, George J, Matthews GV, Law M, Dore GJ.

Hepatol Commun. 2017 Aug 16;1(8):736-747. doi: 10.1002/hep4.1073. eCollection 2017 Oct.

6.

Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review.

Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe AYM, Miller V, Ceccherini-Silberstein F, Bull RA, Douglas MW, Dore GJ, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL.

Hepatol Commun. 2017 May 22;1(5):379-390. doi: 10.1002/hep4.1050. eCollection 2017 Jul. Review.

7.

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.

Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group.

Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6.

PMID:
29310928
8.

Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia.

Hajarizadeh B, Grebely J, Matthews GV, Martinello M, Dore GJ.

J Viral Hepat. 2018 Jun;25(6):640-648. doi: 10.1111/jvh.12852. Epub 2018 Feb 19.

PMID:
29274192
9.

Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database.

Puhr R, Wright ST, Hoy JF, Templeton DJ, Durier N, Matthews GV, Russell D, Law MG.

Sex Health. 2017 Aug;14(4):345-354. doi: 10.1071/SH16151.

PMID:
28482168
10.

HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.

Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV.

Curr HIV/AIDS Rep. 2017 Jun;14(3):110-121. doi: 10.1007/s11904-017-0358-8. Review.

PMID:
28432579
11.

Hepatitis C treatment as prevention: evidence, feasibility, and challenges.

Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ.

Lancet Gastroenterol Hepatol. 2016 Dec;1(4):317-327. doi: 10.1016/S2468-1253(16)30075-9. Epub 2016 Nov 10. Review.

PMID:
28404202
12.

Direct-acting antivirals for acute HCV: how short can we go?

Martinello M, Grebely J, Matthews GV.

Lancet Gastroenterol Hepatol. 2017 May;2(5):316-318. doi: 10.1016/S2468-1253(17)30043-2. Epub 2017 Feb 28. No abstract available.

PMID:
28397692
13.

HCV reinfection incidence among individuals treated for recent infection.

Martinello M, Grebely J, Petoumenos K, Gane E, Hellard M, Shaw D, Sasadeusz J, Applegate TL, Dore GJ, Matthews GV.

J Viral Hepat. 2017 May;24(5):359-370. doi: 10.1111/jvh.12666. Epub 2017 Jan 23.

14.

A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies.

Bartlett SR, Wertheim JO, Bull RA, Matthews GV, Lamoury FM, Scheffler K, Hellard M, Maher L, Dore GJ, Lloyd AR, Applegate TL, Grebely J.

J Viral Hepat. 2017 May;24(5):404-411. doi: 10.1111/jvh.12652. Epub 2016 Nov 24.

15.

Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study.

Martinello M, Gane E, Hellard M, Sasadeusz J, Shaw D, Petoumenos K, Applegate T, Grebely J, Maire L, Marks P, Dore GJ, Matthews GV.

Hepatology. 2016 Dec;64(6):1911-1921. doi: 10.1002/hep.28844. Epub 2016 Oct 27.

PMID:
27639183
16.

Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review.

Jin F, Matthews GV, Grulich AE.

Sex Health. 2017 Feb;14(1):28-41. doi: 10.1071/SH16141.

PMID:
27712618
17.

Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist.

Simpson JD, Matthews GV, Brighton TA, Joseph JE.

Intern Med J. 2016 Sep;46(9):1096-9. doi: 10.1111/imj.13181.

PMID:
27633469
18.

Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men.

Bradshaw D, Raghwani J, Jacka B, Sacks-Davis R, Lamoury F, Down I, Prestage G, Applegate TL, Hellard M, Sasadeusz J, Dore GJ, Pybus OG, Matthews GV, Danta M.

PLoS One. 2016 Sep 1;11(9):e0162002. doi: 10.1371/journal.pone.0162002. eCollection 2016.

19.

Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).

Waziry R, Grebely J, Amin J, Alavi M, Hajarizadeh B, George J, Matthews GV, Law M, Dore GJ.

J Hepatol. 2016 Dec;65(6):1086-1093. doi: 10.1016/j.jhep.2016.08.010. Epub 2016 Aug 26.

PMID:
27569777
20.

Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.

Martinello M, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, Yeung B, Maire L, Iser D, Lloyd A, Thompson A, Sasadeusz J, Haber P, Dore GJ, Matthews GV.

Antivir Ther. 2016;21(5):465. doi: 10.3851/IMP3073. Epub 2016 Aug 10. No abstract available.

PMID:
27509356
21.

Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.

Martinello M, Dore GJ, Skurowski J, Bopage RI, Finlayson R, Baker D, Bloch M, Matthews GV.

Open Forum Infect Dis. 2016 May 18;3(2):ofw105. doi: 10.1093/ofid/ofw105. eCollection 2016 Apr.

22.

Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.

Doyle JS, Grebely J, Spelman T, Alavi M, Matthews GV, Thompson AJ, Dore GJ, Hellard ME; ATAHC Study Group.

PLoS One. 2016 Jun 29;11(6):e0150655. doi: 10.1371/journal.pone.0150655. eCollection 2016.

23.

HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection.

Lamoury FM, Hajarizadeh B, Keoshkerian E, Feld JJ, Amin J, Teutsch S, Matthews GV, Hellard M, Dore GJ, Lloyd AR, Applegate TL, Grebely J; ATAHC Study Group.

BMC Infect Dis. 2016 Jun 1;16:241. doi: 10.1186/s12879-016-1567-2.

24.

Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection.

Sheridan DA, Hajarizadeh B, Fenwick FI, Matthews GV, Applegate T, Douglas M, Neely D, Askew B, Dore GJ, Lloyd AR, George J, Bassendine MF, Grebely J.

Liver Int. 2016 Dec;36(12):1774-1782. doi: 10.1111/liv.13176. Epub 2016 Jul 5.

PMID:
27224844
25.

Prevalence and Disease Burden of HCV Coinfection in HIV Cohorts in the Asia Pacific Region: A Systematic Review and Meta-Analysis.

Martinello M, Amin J, Matthews GV, Dore GJ.

AIDS Rev. 2016 Apr-Jun;18(2):68-80. Review.

PMID:
27196354
26.

Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy.

Audsley J, Robson C, Aitchison S, Matthews GV, Iser D, Sasadeusz J, Lewin SR.

Open Forum Infect Dis. 2016 Feb 12;3(1):ofw035. doi: 10.1093/ofid/ofw035. eCollection 2016 Jan.

27.

Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection.

Hajarizadeh B, Lamoury FM, Feld JJ, Amin J, Keoshkerian E, Matthews GV, Hellard M, Dore GJ, Lloyd AR, Grebely J, Applegate TL; ATAHC Study Group.

Virol J. 2016 Feb 24;13:32. doi: 10.1186/s12985-016-0482-x.

28.

Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.

Martinello M, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, Yeung B, Maire L, Iser D, Lloyd A, Thompson A, Sasadeusz J, Haber P, Dore GJ, Matthews GV.

Antivir Ther. 2016;21(5):425-34. doi: 10.3851/IMP3035. Epub 2016 Feb 11.

PMID:
26867206
29.

HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.

Bartlett SR, Jacka B, Bull RA, Luciani F, Matthews GV, Lamoury FM, Hellard ME, Hajarizadeh B, Teutsch S, White B, Maher L, Dore GJ, Lloyd AR, Grebely J, Applegate TL.

Infect Genet Evol. 2016 Jan;37:252-8. doi: 10.1016/j.meegid.2015.11.028. Epub 2015 Nov 26.

30.

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M.

Lancet HIV. 2015 Aug;2(8):e319-27. doi: 10.1016/S2352-3018(15)00114-9. Epub 2015 Jul 9. Erratum in: Lancet HIV. 2015 Aug;2(8):e316. Lancet HIV. 2015 Oct;2(10):e416.

PMID:
26423374
31.

The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin.

Martinello M, Schteinman A, Alavi M, Williams K, Dore GJ, Day R, Matthews GV.

Antivir Ther. 2016;21(2):127-32. doi: 10.3851/IMP2984. Epub 2015 Aug 24.

PMID:
26304930
32.

Enhancing the detection and management of acute hepatitis C virus infection.

Martinello M, Matthews GV.

Int J Drug Policy. 2015 Oct;26(10):899-910. doi: 10.1016/j.drugpo.2015.07.003. Epub 2015 Jul 16. Review.

PMID:
26254495
33.

The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis.

Lamoury FM, Jacka B, Bartlett S, Bull RA, Wong A, Amin J, Schinkel J, Poon AF, Matthews GV, Grebely J, Dore GJ, Applegate TL.

PLoS One. 2015 Jul 20;10(7):e0131437. doi: 10.1371/journal.pone.0131437. eCollection 2015.

34.

Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.

Lamoury FM, Bartlett S, Jacka B, Hajarizadeh B, Grebely J, Matthews GV, Dore GJ, Applegate TL.

J Mol Diagn. 2015 Sep;17(5):583-9. doi: 10.1016/j.jmoldx.2015.05.003. Epub 2015 Jul 4.

35.

Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.

Alavi M, Spelman T, Matthews GV, Haber PS, Day C, van Beek I, Walsh N, Yeung B, Bruneau J, Petoumenos K, Dolan K, Kaldor JM, Dore GJ, Hellard M, Grebely J; ATAHC Study Group.

Int J Drug Policy. 2015 Oct;26(10):976-83. doi: 10.1016/j.drugpo.2015.05.003. Epub 2015 May 21.

36.

Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Matthews GV, Neuhaus J, Bhagani S, Mehta SH, Vlahakis E, Doroana M, Naggie S, Arenas-Pinto A, Peters L, Rockstroh JK; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:129-36. doi: 10.1111/hiv.12241.

37.

A comparison of seminal hepatitis C virus (HCV) RNA levels during recent and chronic HCV infection in HIV-infected and HIV-uninfected individuals.

Bradshaw D, Lamoury F, Catlett B, Applegate TL, Mcallister J, Dore GJ, Matthews GV, Danta M.

J Infect Dis. 2015 Mar 1;211(5):736-43. doi: 10.1093/infdis/jiu550. Epub 2014 Oct 6.

38.

Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.

Applegate TL, Gaudieri S, Plauzolles A, Chopra A, Grebely J, Lucas M, Hellard M, Luciani F, Dore GJ, Matthews GV.

Antivir Ther. 2015;20(2):199-208. doi: 10.3851/IMP2821. Epub 2014 Aug 8.

39.

Dynamics of HCV RNA levels during acute hepatitis C virus infection.

Hajarizadeh B, Grebely J, Applegate T, Matthews GV, Amin J, Petoumenos K, Hellard M, Rawlinson W, Lloyd A, Kaldor J, Dore GJ; ATAHC study group.

J Med Virol. 2014 Oct;86(10):1722-9. doi: 10.1002/jmv.24010. Epub 2014 Jul 8.

40.

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.

Achhra AC, Boyd MA, Law MG, Matthews GV, Kelleher AD, Cooper DA.

PLoS One. 2014 Jun 26;9(6):e99530. doi: 10.1371/journal.pone.0099530. eCollection 2014.

41.

Reply: To PMID 24449403.

Holmes JA, Matthews GV, Thompson AJ; CHARIOT Study Group.

Hepatology. 2015 Jan;61(1):409. doi: 10.1002/hep.27255. Epub 2014 Nov 20. No abstract available.

PMID:
24915780
42.

Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels.

Avihingsanon A, Jitmitraparp S, Tangkijvanich P, Ramautarsing RA, Apornpong T, Jirajariyavej S, Putcharoen O, Treeprasertsuk S, Akkarathamrongsin S, Poovorawan Y, Matthews GV, Lange JM, Ruxrungtham K; HIV-NAT125 study team.

J Gastroenterol Hepatol. 2014 Sep;29(9):1706-14. doi: 10.1111/jgh.12613.

PMID:
24730732
43.

ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.

Holmes JA, Roberts SK, Ali RJ, Dore GJ, Sievert W, McCaughan GW, Crawford DH, Cheng WS, Weltman MD, Bonanzinga S, Visvanathan K, Sundararajan V, Desmond PV, Bowden DS, Matthews GV, Thompson AJ; CHARIOT Study Group.

Hepatology. 2014 Jun;59(6):2152-60. doi: 10.1002/hep.27022. Epub 2014 Apr 25.

PMID:
24449403
44.

Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection.

Feld JJ, Grebely J, Matthews GV, Applegate T, Hellard M, Sherker A, Cherepanov V, Petoumenos K, Yeung B, Kaldor JM, Lloyd AR, Dore GJ.

PLoS One. 2013 Nov 20;8(11):e80003. doi: 10.1371/journal.pone.0080003. eCollection 2013.

45.

Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.

Taylor LE, Swan T, Matthews GV.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S118-24. doi: 10.1093/cid/cit326. Review.

46.

Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.

Grebely J, Matthews GV, Lloyd AR, Dore GJ.

Clin Infect Dis. 2013 Oct;57(7):1014-20. doi: 10.1093/cid/cit377. Epub 2013 May 31.

PMID:
23728143
47.

Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.

Matthews GV, Ali RJ, Avihingsanon A, Amin J, Hammond R, Bowden S, Lewin SR, Sasadeusz J, Littlejohn M, Locarnini SL, Ruxrungtham K, Dore GJ.

PLoS One. 2013 Apr 9;8(4):e61297. doi: 10.1371/journal.pone.0061297. Print 2013.

48.

Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.

Grebely J, Feld JJ, Applegate T, Matthews GV, Hellard M, Sherker A, Petoumenos K, Zang G, Shaw I, Yeung B, George J, Teutsch S, Kaldor JM, Cherepanov V, Bruneau J, Shoukry NH, Lloyd AR, Dore GJ.

Hepatology. 2013 Jun;57(6):2124-34. doi: 10.1002/hep.26263. Epub 2013 May 8.

49.

Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.

Matthews GV, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, Sasadeusz J, Revill PA, Littlejohn M, Hoy JF, Finlayson R, Ruxrungtham K, Saulynas M, Locarnini S, Thio CL.

Clin Infect Dis. 2013 May;56(9):e87-94. doi: 10.1093/cid/cit002. Epub 2013 Jan 11.

50.

Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.

Grebely J, Hellard M, Applegate T, Petoumenos K, Yeung B, Feld JJ, Rawlinson W, Lloyd AR, George J, Kaldor JM, Dore GJ, Matthews GV; ATAHC Study Group.

AIDS. 2012 Aug 24;26(13):1653-61.

Supplemental Content

Loading ...
Support Center